Paget’s Disease Treatment Market By Drug Class (Bisphosphonates [Nitrogen-Containing Bisphosphonates, Non-Nitrogen Bisphosphonates], Calcitonin Analogues [Salmon Calcitonin, Human Calcitonin], Analgesics & NSAIDs [Acetaminophen, Ibuprofen, Other Anti-Inflammatory Medications], Nutritional Supplements [Calcium, Vitamin D]); By Specific Drug / Brand Formulations (Zoledronic Acid [Reclast and Other Zoledronic Acid Formulations], Risedronate Sodium [Actonel and Generic Formulations], Alendronate [Fosamax and Generic Formulations], Pamidronate [Aredia], Other Formulations); By Route of Administration (Intravenous (IV) Administration, Oral Administration, Nasal and Other Non-Oral Supportive Administration); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies & Drug Stores); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Is the Global Paget’s Disease Treatment Market Expanding Through Advanced Bisphosphonate Therapies and Improved Bone Disease Management?

The Global Paget’s Disease Treatment Market was valued at an estimated USD 109.58 million in 2025 and is projected to reach USD 139.67 million by 2032, expanding at a CAGR of 3.53% during 2026–2032, according to Strategic Market Research.

 

An April 2026 study published in Rheumatology, involving 143 patients at University Hospital Southampton, reported an average patient age of 86 years. Pelvic bone involvement was identified in 95 patients (66.4%), while 39 experienced bone pain and 36 were diagnosed incidentally through imaging, highlighting the importance of clinical assessment among older adults.

 

Bisphosphonates remain the principal pharmaceutical treatment, particularly intravenous zoledronic acid. The same study reported that 52 patients (36.1%) received bisphosphonates, including 73.3% of patients managed through rheumatology. Treatment opportunities remain concentrated among symptomatic individuals requiring specialist care rather than routine long-term drug administration.

 

Supportive therapy and orthopedic interventions represent additional treatment categories. The 2024 Italian clinical recommendations reported mild hypocalcemia in 2–6% of patients receiving zoledronic acid, reinforcing the importance of calcium and vitamin D management. A 2023 systematic review covering 58,695 individuals reported pooled revision rates of 4.4% following hip replacement and 2.2% following knee replacement among the reviewed Paget's disease surgical populations.

 

Market growth is primarily associated with improved diagnosis, appropriate bisphosphonate utilization, and treatment of advanced skeletal complications. However, the prolonged effectiveness of zoledronic acid and declining disease frequency in some populations limit repeat-treatment volumes, contributing to the market's moderate growth outlook.

 

Which Subsegments Lead the Paget’s Disease Treatment Market, and Which Are Expected to Grow the Fastest Through 2032?

By Drug Class: Bisphosphonates Lead Sustained Disease Control

Leading and Fastest-Growing Subsegment – Bisphosphonates

Bisphosphonates remain the preferred and most effective pharmacological treatment for Paget’s disease of bone, owing to their ability to suppress excessive bone turnover, control disease activity, and provide sustained clinical remission. Within the Paget’s Disease Treatment Market, bisphosphonates accounted for an estimated 68% market share, representing USD 74.51 million in 2025, and are projected to expand at a CAGR of 3.90% during 2026–2032. Zoledronic acid continues to strengthen treatment adoption through its prolonged therapeutic effectiveness and single-infusion administration.

 

By Specific Drug Formulation: Zoledronic Acid Leads Single-Infusion Treatment

Leading and Fastest-Growing Subsegment – Zoledronic Acid (Reclast)

Zoledronic acid, marketed as Reclast or Aclasta, remains a preferred first-line treatment for Paget’s disease of bone in men and women due to its sustained effectiveness in controlling abnormal bone remodeling. Within the Paget’s Disease Treatment Market, zoledronic acid holds the largest formulation share at approximately 43%, equivalent to USD 47.12 million in 2025. It is also projected to register the fastest formulation growth, advancing at a CAGR of 4.30% during 2026–2032, supported by its prolonged therapeutic efficacy and single-infusion treatment approach.

 

By Route of Administration: Intravenous Therapy Leads Prolonged Disease Suppression

Leading and Fastest-Growing Subsegment – Intravenous (IV) Administration

Intravenous administration holds a leading position in the Paget's Disease Treatment Market, accounting for an estimated 49% market share, equivalent to USD 53.69 million in 2025, and is projected to expand at a CAGR of 4.20% during 2026–2032. A single intravenous infusion of zoledronic acid is widely recommended as first-line therapy for Paget's disease of bone due to its sustained suppression of abnormal bone turnover, high remission rates, and prolonged therapeutic effectiveness. Its established clinical efficacy supports continued adoption across hospitals and specialty treatment centers.

 

By Distribution Channel: Hospital Pharmacies Lead While Digital Prescription Access Expands

Leading Subsegment – Hospital Pharmacies

Hospital pharmacies hold a leading position in the Paget’s Disease Treatment Market, accounting for an estimated 46% market share, valued at USD 50.41 million in 2025, and are projected to expand at a CAGR of 3.70% during 2026–2032. Their prominence reflects their central role in coordinating the distribution, preparation, and clinical monitoring of bisphosphonate therapies, particularly intravenous zoledronic acid. Hospital-based treatment facilities also provide specialist supervision, renal function assessment, and calcium monitoring, supporting safe medication administration and effective long-term management of Paget’s disease of bone.

Fastest-Growing Subsegment – Online Pharmacies & Drug Stores

Online pharmacies and digital drugstores play a specialized supportive and logistical role in the Paget's Disease Treatment Market, accounting for an estimated 9% market share, valued at USD 9.86 million in 2025, and are projected to register the fastest CAGR of 5.15% during 2026–2032. Their growing presence reflects improved access to prescribed oral bisphosphonates, calcium supplements, and vitamin D preparations. Digital prescription services, home delivery, and medication refill programs help patients maintain treatment continuity, particularly those requiring long-term monitoring and supportive bone health management.

 

By Geography: Europe Leads Specialist Bone Care While Asia-Pacific Expands Treatment Access

Leading Region – Europe

Europe holds the largest estimated share of the Paget's Disease Treatment Market at 39%, valued at USD 42.74 million in 2025, and is projected to grow at a CAGR of 2.90% during 2026–2032. Treatment adoption across European countries is influenced by established clinical guidelines, changing regional disease prevalence, and increasing preference for bisphosphonate therapies, particularly zoledronic acid. Established healthcare infrastructure, specialist rheumatology services, and continued clinical emphasis on managing bone pain and abnormal bone remodeling support Europe's leading market position.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific accounted for an estimated 18% of the global Paget’s Disease Treatment Market, valued at USD 19.72 million in 2025, and is projected to register the fastest regional CAGR of 5.38% during 2026–2032. Treatment adoption remains influenced by the relatively low prevalence of Paget’s disease of bone among Asian populations compared with Western countries. Differences in diagnostic awareness, access to specialist care, and regulatory approvals for bisphosphonate therapies further influence treatment availability across Japan, China, India, and other regional healthcare markets.

 

Which Companies Are Leading the Paget’s Disease Treatment Market Through Advanced Bisphosphonate Therapies and Bone-Health Pharmaceuticals?

Novartis AG – Intravenous Zoledronic Acid and Long-Term Disease Suppression

Novartis has played an important role in Paget’s disease treatment through Reclast (zoledronic acid), a nitrogen-containing bisphosphonate administered intravenously. The formulation inhibits excessive osteoclast-mediated bone resorption and helps restore biochemical control in patients with active disease. Reclast's approved Paget’s disease regimen consists of a single 5 mg infusion administered over at least 15 minutes, with extended remission possible after treatment.

Clinical evidence from a comparative study involving 357 patients demonstrated a 96.0% therapeutic response with zoledronic acid compared with 74.3% for oral risedronate at six months. Serum alkaline phosphatase normalization was achieved in 88.6% of zoledronic acid recipients, demonstrating the clinical effectiveness of potent intravenous antiresorptive therapy. Novartis's contribution helped establish single-infusion treatment as an important therapeutic approach, with implications for hospital infusion services and long-term disease management.

Merck & Co., Inc. – Oral Alendronate Therapy and Biochemical Disease Control

Merck contributed to Paget’s disease treatment through Fosamax (alendronate sodium), an oral nitrogen-containing bisphosphonate that suppresses excessive skeletal resorption. Its Paget’s disease regimen involves 40 mg daily for six months, providing an established oral treatment alternative for patients receiving outpatient care.

FDA prescribing information documents two controlled studies evaluating alendronate in patients with moderate-to-severe Paget’s disease. Approximately 85% of alendronate-treated patients achieved the defined biochemical response, compared with 30% receiving etidronate and 0% receiving placebo. The studies also documented improved bone remodeling and formation of normal lamellar bone following treatment. Fosamax's clinical record supports the continuing role of oral bispho:sphonates in disease control and their relevance to retail pharmacy distribution and generic pharmaceutical competition.

Other Companies and Their Roles in Paget’s Disease Treatment

• Pfizer Inc.: Provides intravenous pamidronate disodium for moderate-to-severe Paget’s disease. Clinical data show that at least 50% of treated patients achieved a 50% or greater reduction in key biochemical markers.

• Eli Lilly and Company: Has historical involvement in calcitonin-based bone disease treatment, a therapeutic approach used when conventional bisphosphonate treatment is unsuitable.

• GlaxoSmithKline plc (GSK): Has broader experience in pharmaceutical development, although a current, directly attributable Paget’s disease treatment product was not verified.

• Johnson & Johnson: Participates in orthopedic technologies and musculoskeletal care, relevant to managing severe skeletal and joint complications associated with Paget’s disease.

• AstraZeneca: Has broader pharmaceutical research capabilities, although a currently marketed Paget’s disease-specific treatment was not verified.

 

Analyst Commentary: How Will Long-Term Remission and Generic Competition Shape Future Growth?

The Paget’s Disease Treatment Market is increasingly focused on achieving long-term disease remission rather than repeated symptom management. Intravenous bisphosphonates, particularly zoledronic acid, are strengthening treatment outcomes through sustained suppression of abnormal bone remodeling. However, declining disease incidence in established markets and the availability of low-cost generics may limit pharmaceutical revenue growth. Future opportunities will depend on earlier diagnosis, improved specialist treatment access, and effective management of skeletal complications in aging populations.

 

Paget’s Disease Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 109.58 Million
Revenue Forecast in 2032	USD 139.67 Million
Overall Growth Rate	CAGR of 3.53% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Drug Class, By Specific Drug / Brand Formulations, By Route of Administration, By Distribution Channel, By Geography
By Drug Class	Bisphosphonates (Nitrogen-Containing Bisphosphonates, Non-Nitrogen Bisphosphonates), Calcitonin Analogues (Salmon Calcitonin, Human Calcitonin), Analgesics & NSAIDs (Acetaminophen, Ibuprofen, Other Anti-Inflammatory Medications), Nutritional Supplements (Calcium, Vitamin D)
By Specific Drug / Brand Formulations	Zoledronic Acid (Reclast and Other Zoledronic Acid Formulations), Risedronate Sodium (Actonel and Generic Formulations), Alendronate (Fosamax and Generic Formulations), Pamidronate (Aredia), Other Formulations
By Route of Administration	Intravenous (IV) Administration, Oral Administration, Nasal and Other Non-Oral Supportive Administration
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies & Drug Stores
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing diagnosis of Paget’s disease among aging populations, continued use of bisphosphonate therapies, preference for intravenous zoledronic acid, demand for long-term suppression of abnormal bone remodeling, specialist rheumatology and bone-health services, management of Paget’s-related bone pain and skeletal complications, and improving access to pharmaceutical treatment and supportive care
Customization Option	Available upon request